Patrick Deval L - Nov 1, 2023 Form 4 Insider Report for Cerevel Therapeutics Holdings, Inc. (CERE)

Role
Director
Signature
/s/ Mark Bodenrader, as Attorney-in-Fact
Stock symbol
CERE
Transactions as of
Nov 1, 2023
Transactions value $
-$373,009
Form type
4
Date filed
11/3/2023, 04:15 PM
Previous filing
Sep 19, 2023
Next filing
Dec 19, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CERE Common Stock Options Exercise $380K +30.1K +918.04% $12.62 33.4K Nov 1, 2023 Direct F1, F2
transaction CERE Common Stock Sale -$753K -30.1K -90.18% $25.00 3.28K Nov 1, 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CERE Stock Option (Right to Buy) Options Exercise $0 -30.1K -70.59% $0.00 12.6K Nov 1, 2023 Common Stock 30.1K $12.62 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 12, 2022 adopted by the Reporting Person.
F2 Includes 3,282 Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan that were previously reported by the Reporting Person.
F3 This option shall vest in thirty-six (36) equal monthly installments over three (3) years, with the first installment vested on February 1, 2021.